Entries by oncotron

Curve Therapeutics featured on Biotech TV

Curve Therapeutics CEO Simon Kerry spoke with Amy Brown of Biotech TV on the background, science, and development plans for the Company. Curve CSO Ali Tavassoli also spoke with Amy for a deep dive on the science behind Curve’s mammalian cell-based Microcycle® discovery platform. Simon’s episode is available here while Ali’s is available here.

Curve Therapeutics Co-Founder and CSO Professor Ali Tavassoli awarded the Royal Society of Chemistry’s Interdisciplinary Prize

Awarded in recognition of excellence in research and innovation and contribution to scientific progress Reflects the revolutionary potential of Curve’s gene-encoded Microcycle® platform to unlock the therapeutic potential of intracellular targets Southampton, UK, 25 June 2025 – Curve Therapeutics (“Curve” or the “Company”), a private biotechnology company building a pipeline of innovative cyclic peptide and […]

Bio€quity Europe

Bio€quity Europe Bruges, Belgium May 12-14, 2025 Simon Kerry, CEO attending

Anglonordic Life Sciences Conference

Anglonordic Life Sciences Conference April 3, 2025 London, UK Simon Kerry, CEO & Cora Griffin, Head of Business Development attending

BIO-Europe Spring

BIO-Europe Spring March 17-19, 2025 Milan, Italy Cora Griffin, Head of Business Development attending

How Curve’s Proprietary Microcycle® Discovery Platform is Reinventing Drug Discovery

Curve Perspectives article – Ali Tavassoli With its powerful Microcycle platform technology, Curve Therapeutics is building a pipeline of innovative drugs with a focus on cancer, immunology and inflammation. Our Co-Founder and Chief Scientific Officer, Ali Tavassoli, explains more. Simon Kerry and I co-founded Curve in 2019 with a vision to transform the lives of […]

2024 a transformational year of progress: A note from the CEO

2024 has been a transformational year for Curve.  We kicked off the year with a significant  Series A financing, raising £40.5 million from a world class syndicate which includes our existing blue chip investors Advent Life Sciences and Epidarex Capital, alongside new investment from Pfizer Ventures, Columbus Venture Partners and British Patient Capital. The financing […]